Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17200860 | 0.73 | MAOA (0.41) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL17026534 | 0.73 | POLA1 (0.34) | — | |
| SCHEMBL597333 | 0.68 | DPP4 (0.49) | NPC1RAB9AALDH1A1 | |
| SCHEMBL22005789 | 0.66 | DPP4 (0.47) | NPC1RAB9AALDH1A1 | |
| SCHEMBL15127496 | 0.66 | FYN (0.42) | MEN1KMT2ASRD5A1ALDH1A1CYP3A4 | |
| SCHEMBL414198 | 0.64 | NPC1 (0.52) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL31498326 | 0.64 | SRD5A1 (0.38) | MEN1KMT2ASRD5A1ALDH1A1CYP3A4 | |
| SCHEMBL23555197 | 0.64 | ACHE (0.39) | ALDH1A1CYP3A4 | |
| SCHEMBL597666 | 0.62 | SRD5A1 (0.42) | NPC1RAB9ASRD5A1ALDH1A1CYP3A4 | |
| SCHEMBL15759141 | 0.62 | MEN1 (0.43) | NPC1RAB9AMEN1KMT2ASRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9759726-B2 | Reactive labelling compounds and uses thereof | ACADEMIA SINICA (TW) | 2017-09-12 | — | — | US | disclosed |
| US-9547009-B2 | Benzocyclooctyne compounds and uses thereof | ACADEMIA SINICA (TW) | 2017-01-17 | — | — | US | disclosed |
| US-20150309041-A1 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | ACADEMIA SINICA (TW) | 2015-10-29 | — | — | US | disclosed |
| US-20150241439-A1 | BENZOCYCLOOCTYNE COMPOUNDS AND USES THEREOF | ACADEMIA SINICA (TW) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150309041-A1 | REACTIVE LABELLING COMPOUNDS AND USES THEREOF | MPI, AADAC, PAICS | NPC1 617/4885RAB9A 1676/4885MEN1 2425/4885 |
| US-20150241439-A1 | BENZOCYCLOOCTYNE COMPOUNDS AND USES THEREOF | AADAC, TBCA, SPG11 | NPC1 3214/4885RAB9A 3289/4885MEN1 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.